A phase I study of DRX-065 in healthy volunteers

Trial Profile

A phase I study of DRX-065 in healthy volunteers

Phase of Trial: Phase I

Latest Information Update: 14 Mar 2018

At a glance

  • Drugs Pioglitazone deuterated (Primary) ; Pioglitazone
  • Indications Adrenomyeloneuropathy; Non-alcoholic steatohepatitis
  • Focus Adverse reactions; Pharmacokinetics
  • Most Recent Events

    • 14 Mar 2018 Status changed from planning to recruiting, According to a DeuteRx media release.
    • 14 Sep 2016 New trial record
    • 22 Aug 2016 According to a DeuteRx media release, the U.S. Food and Drug Administration (FDA) has completed its review of the Company's investigational new drug (IND) application for DRX-065 and has determined that a Phase 1 clinical study in healthy volunteers can be initiated. Dosing is expected to be completed in September 2016.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top